Physician profile
Michael G Raymond
NPI 1184607624
$17,729.72
in general payments reported to CMS, 2019-2025
72 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,663 · 2020: $1,209 · 2021: $3,674 · 2022: $5,179 · 2023: $3,517 · 2024: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,638.15 | 2019-2023 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $1,003.14 | 2019-2024 | Enhertu, Calquence |
| Janssen Biotech, INC. | $980.15 | 2019-2023 | Darzalex, Imbruvica |
| Incyte Corporation | $977.53 | 2020-2024 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $910.51 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $860.11 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $818.01 | 2019-2023 | Keytruda, Lynparza |
| Genentech USA, INC. | $801.92 | 2019-2023 | Rozlytrek, Avastin, Gavreto |
| Amgen INC. | $653.86 | 2019-2023 | Nplate, Lumakras, Xgeva |
| Exelixis INC. | $652.59 | 2019-2024 | Cabometyx |
| Pfizer INC. | $617.79 | 2019-2023 | |
| Seagen INC. | $601.58 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Lilly USA, LLC | $551.22 | 2019-2023 | Jaypirca, Verzenio |
| Kite Pharma, INC. | $540.46 | 2019-2023 | Yescarta |
| Beigene USA, INC. | $492.35 | 2020-2024 | Brukinsa |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.